This study aims to evaluate the impact of anti-PD-1 therapy on PD-L1 expression and glucose metabolism in normal organs in patients with advanced NSCLC using a dual SPECT/CT and PET/CT imaging approach. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.